BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

960 related articles for article (PubMed ID: 28778958)

  • 1. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
    Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.
    Spindler KG
    Acta Oncol; 2017 Jan; 56(1):7-16. PubMed ID: 28010185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
    Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
    PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
    Hamfjord J; Guren TK; Dajani O; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P; Lingjærde OC; Tveit KM; Kure EH; Pallisgaard N; Spindler KG
    Ann Oncol; 2019 Jul; 30(7):1088-1095. PubMed ID: 31046124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer.
    Spindler KL; Appelt AL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
    Int J Cancer; 2014 Dec; 135(12):2984-91. PubMed ID: 24798213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
    Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
    Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
    Yang C; Zou K; Zheng L; Xiong B
    BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
    Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
    Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
    Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
    Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
    J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer.
    Spindler KG; Demuth C; Sorensen BS; Johansen JS; Nielsen D; Pallisgaard N; Hoegdall E; Pfeiffer P; Vittrup Jensen B
    Tumour Biol; 2018 Nov; 40(11):1010428318811207. PubMed ID: 30486767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
    Ørntoft MW; Jensen SØ; Øgaard N; Henriksen TV; Ferm L; Christensen IJ; Reinert T; Larsen OH; Nielsen HJ; Andersen CL
    Int J Cancer; 2021 Apr; 148(7):1665-1675. PubMed ID: 33320961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
    Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
    Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.
    Berger AW; Schwerdel D; Welz H; Marienfeld R; Schmidt SA; Kleger A; Ettrich TJ; Seufferlein T
    PLoS One; 2017; 12(3):e0174308. PubMed ID: 28328955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
    Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
    Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA is effective for detection of KRAS mutation in colorectal cancer: a meta-analysis.
    Tang M; Deng Z; Li B; Peng Y; Song M; Liu J
    Int J Biol Markers; 2017 Oct; 32(4):e421-e427. PubMed ID: 28885658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
    Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
    Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.